Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial - Yue-Mei Hu; Zhao-Feng Bi; Ya Zheng; Li Zhang; Feng-Zhu Zheng; Kai Chu; Ya-Fei Li; Qi Chen; Jia-Li Quan; Xiao-Wen Hu; Xing-Cheng Huang; Kong-Xin Zhu; et al. (Science Bulletin, 2023)